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goodness-of-fit of the final model. Optimism-corrected 
survival proportions were calculated. All analyses were 
performed according to the TRIPOD statement. 
 
Results: 28 (45%) patients died from PCa after mean (±SD) 82 
(±36) months. Median total follow-up was 78 months (range 
5-139). In total, 36 patients (58%) patients died after mean 
84 (±40) months. PSA doubling time (PSADT) remained as a 
predictive factor for both PCaSM and OM: corrected hazard 
ratio’s (HR’s) 0.92 (95%-CI: 0.86-0.98, p=0.02) and 0.94 (95%-
CI: 0.90-0.99, p=0.01), respectively. The adjusted C-statistics 
were 0.71 and 0.69, respectively. Predictive ability 
(calibration) was good up to 96 months follow-up. Over 80% 
of patients can survive 8 years if PSADT>24 months (PCaSM) 
and >33 months (OM) (Figure 1).  
 
Figure 1: Prostate cancer specific survival (PCaSS) and overall 
survival (OS) as a function of PSADT. 
 
Conclusion: A PSADT >24 months and >33 months can result 
in a high probability (>80%) of prostate cancer specific and 
overall survival 8 years after TS I-125 BT. Larger series and 
external validation are necessary. 
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Purpose or Objective: Locally recurrent prostate cancer 
reirradiation may lead to urethral stricture and increase of 
urinary symptoms including urinary retention. Such patients 
may undergo urethretomy or transurethral resection of the 
prostate (TURP), which may cause urinary incontinence. Our 
purpose was to evaluate risk of urinary incontinence after 
salvage high-dose-rate brachytherapy (HDR BT) with or 
without urological intervention.  
 
Material and Methods: We included in the analysis all salvage 
HDR BT patients with at least 6 months of follow-up. Urinary 
retention, urological interventions and urinary incontinence 
rates were assessed. 5-year adverse event-free survivals were 
calculated.  
 
Results: One hundred and two men were enrolled in this 
retrospective analysis. Median age was 71 years (57-81). 
Median follow-up was 37 months (6-76). Twenty-three men 
(23%) underwent urological intervention after salvage HDR 
BT. Fourteen of them suffered from urinary retention, 9 men 
were treated due to refractory obstructive urinary symptoms. 
TURP or urethretomy was performed 15 and 12 times, 
respectively. Four patients underwent combination of both. 
Twelve patients suffered from urinary incontinence with no 
intervention, twenty men developed it after urological 
intervention. Five patients needed suprapubic catheter. 5-
year urological intervention-free survival was 65%. 5-year 
urinary incontinence-free survival (UIFS) was 69%. Any 
urological intervention was linked with higher urinary 
incontinence probability (4-year UIFS 88% vs 5%, p-0.0000; 
HR-14.05; 95% CI 13.25-14.85).  
 
Conclusion: There is high probability of urinary incontinence 
in salvage HDR BT prostate cancer patients after urological 
intervention (TURP/urethrotomy). Therefore patients 
suffering from refractory obstructive urinary symptoms 
without urinary retention should be carefully evaluated and 
counseled before any urological management. 
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Purpose or Objective: To evaluate the technical feasibility 
and safety of focal MRI guided HDR brachytherapy as a 
primary, salvage or secondary salvage treatment in 37 
patient with a localized (recurrent) prostate cancer. 
 
Material and Methods: From May 2013 until October 2015, 37 
patients were treated with focal MRI guided HDR 
brachytherapy. 26 patients received MRI guided primary focal 
HDR brachytherapy, 8 patients salvage treatment and 3 
patient secondary salvage treatment. The prescribed dose to 
the PTV was 19 Gy, with strict limitations to the organs at 
risk. Patients with a (recurrent) PA proven prostate cancer 
were included in this evaluation. Before treatment, a 
diagnostic multiparametric MR was performed to define the 
tumor region. In patients with recurrent disease, a choline 
PET scan or PSMA scan was performed to exclude patients 
with early distant metastasis. The treatment was performed 





After ultrasound guided insertion of the catheters, an MRI of 
the prostate was performed for the reconstruction of the 
inserted catheters. Consequently, a per-operative treatment 
plan was performed prior to dose delivery. Toxicity was 
measured using the CTCAE version 4. 
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Results: For all patients, the treatment was tolerated well. 
In some patients, a lower dose to the PTV was given in order 
to protect the organs at risk. This was especially the case in 
patients that received a second salvage treatment. No 
patients developed a new grade 3 (or more) toxicity. One 
patient developed an acute urinary retention after primary 
focal HDR brachytherapy. Other grade 2 toxicity was 
uncommon in patients that received HDR brachytherapy as a 
primary treatment. In patients with a salvage treatment, 
grade 2 toxicity such as urinary infections and incontinence 
occurred in 3 of 8 patients. The 3 patients that received a 
second salvage treatment had not developed severe toxicity. 
However, follow up of these patients is very short (1-6 
months). 
 
Conclusion: Focal HDR brachytherapy as focal, salvage and 
secondary salvage treatment seems clinically feasible and 
safe. It could be a promising treatment modality to reduce 
severe side effect in patients with primary prostate cancer. 
Furthermore, it could postpone hormonal treatment in 
patients with recurrent or secondary recurrent prostate 
cancer. 
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In this contribution the physical properties of protons and 
other Ions will be outlined and the differences between 
different ions will be highlighted. The relevance of these 
properties with respect to radiotherapy will be discussed. In 
detail the physical properties to be discussed are the depth 
dose distribution, lateral scattering and energy loss 
straggling. These quantities will mainly affect the dose 
conformation potential of the various ion beams through the 
distal and lateral penumbra and the dose in the entrance 
region. The most important difference here arises through 
the multiple small angle scattering of particles which is 
strongly depend on the mass of the Ions: for heavier Ions, the 
lateral penumbra will be significantly smaller than for 
protons.  
Another very important physical paramter is the stopping 
power of the particles, as this quantity will influence the 
radiobiological properties of the differnt ions. The stopping 
power describes the energy loss of a particle per pathlength 
and be accuaretly calculated using the Bethe formalism. 
More important for the radiobiological effects is the linear 
energy transfer (LET), which is often used synomyously to 
stopping power. LET describes the eneryg transferred into a 
narrow region around the primary ion track and can also be 
calculated using the Bethe formalism. While the LET of a 
pure beam of ions with a fixed energy is well defined, the 
LET of a mixed radiation field is more complex. The reason 
for that is, that in a mixed radiation field, LET has to be 
averaged over the different Ions contributing. This is often 
done by using the so-called "dose averaged LET", where the 
LET of each particle is weighted according to the dose it is 
contributing. Another way of defining an average LET is by 
averaging over the fluence (or alternatively over the track 
length). Both average LET definitions are being used for 
various biological applications and will be presented. When 
discussing the relative biological effectiveness (RBE) of ion 
beams, one has to be aware of this difference.  
Finally the nuclear fragmentation of ions may lead to strong 
differences in the spectrum, or mixture of ions of different 
kind at different points in depth. The relevance of these 
nuclear fargments becomes clear, when comparing the dose 
just behind the Bragg peak of a primary carbon ion beam 
(which is completely due to light fragments) and a proton 
beam (which is completely due to protons). An overview of 
the characteristics of the fragmentation spectra of Ions will 
therefore also be given. 
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Both, carbon ions and protons show an inverted depth dose 
profile (Bragg-peak) and allow for highly conformal 
irradiations of tumors in the neighborhood of radiosensitive 
normal tissues. Heavier ions such as carbon ions additionally 
show an increased linear energy transfer (LET) towards the 
distal edge of the Bragg-peak leading to an increased relative 
biological effectiveness (RBE) with respect to photon 
irradiations [1]. While the RBE for clinical proton beams is 
currently fixed to 1.1, the RBE of carbon ion varies 
significantly within the treatment field and has to be 
calculated by RBE-models. The RBE-models, however, 
introduce additional uncertainties, which have to be 
considered in treatment planning and especially in clinical 
dose prescription. 
As protons and carbon ions exhibit almost comparable 
geometrical accuracy, the clinical question whether protons 
or carbon will be more beneficial for the patient mainly 
addresses the independent role of the high-LET effect in 
radiotherapy. The answer to this question is related to the 
following subquestions: (i) How accurate is the applied RBE-
model? (ii) Is a fixed proton RBE of 1.1 accurate enough for 
all field configurations? (iii) Which tumor types are best 
suited for heavy ions? (iv) Can high-LET irradiations overcome 
radioresistance of hypoxic tumors? 
While questions (i) and (ii) refer to normal tissue reactions, 
(iii) and (iv) address the impact of tumor-specific resistance 
factors on the radiation response. An additional benefit of 
heavy ions will strongly depend on the differential response 
between tumor and normal tissue. Although the final prove or 
disprove of advantages has to be provided by prospectively 
randomized clinical trials, ongoing preclinical experiments 
can help to study the subquestions (i)-(iv) separately, i.e. to 
benchmark RBE-models (e.g. LEM I vs IV), to select suitable 
tumor entities, to setup clinical trials and to generally 
improve the understanding of normal and tumor tissue 
response after high- vs. low-LET irradiation. 
The presentation will give an introduction on the concepts 
describing the response to high-LET irradiations and will give 
an overview on the available in vivo data with focus on the 
current answers to the above questions. 
References 
[1] Suit H, DeLaney T, Goldberg S et al. Proton vs carbon ion 
beams in the definitive radiation treatment of cancer 
patients. Radiother Oncol 2010;95:3-22. 
 
SP-0043  
How strong is the current clinical evidence for protons and 
heavy ions ? 
P. Fossati
1Fondazione CNAO Centro Nazionale Adroterapia Oncologica, 
Clinical Department, Pavia, Italy 
1,2 
2European Institute of Oncology, Radiotherapy Division, 
Milano, Italy 
 
Particle therapy has been available in hospital setting since 
1991. About 100.000 Patients have been treated worldwide 
with protontherapy and more than 10.000 patients have been 
treated with carbon ion radiotherapy. After almost 15 years 
in which this modality was available only in few centres in 
the last ten years the number of new particle facilities has 
steeply increased in the US and in Asia and more recently 
several facilities have been planned in Europe. Protontherapy 
has traditionally been used because of its strong preclinical 
rationale based on its favourable physical properties that 
allow a substantial reduction in integral dose and exposure of 
non-target tissues. Carbon ion radiotherapy has mainly been 
used for its radiobiological property that may offer an 
advantage in the treatment of macroscopic tumours made of 
